
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/base_style-CPPDhfna.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-BepKMsUl.js"></script>

  <link rel="stylesheet" href="/static/assets/article_style-DUfI1jZp.css" />
<link rel="stylesheet" href="/static/assets/style-BOrsu84o.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-D3wJHomh.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="E0CA1C88930A0593001C88001E530E08.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="eclinm">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12273842/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="eClinicalMedicine">
<meta name="citation_title" content="Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis">
<meta name="citation_author" content="Youwen Zhu">
<meta name="citation_author_institution" content="Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China">
<meta name="citation_author" content="Kun Liu">
<meta name="citation_author_institution" content="Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China">
<meta name="citation_author" content="Steven T Rosen">
<meta name="citation_author_institution" content="Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, CA, USA">
<meta name="citation_author" content="Wei Liu">
<meta name="citation_author_institution" content="Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China">
<meta name="citation_author_institution" content="National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China">
<meta name="citation_author" content="Hong Zhu">
<meta name="citation_author_institution" content="Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China">
<meta name="citation_author_institution" content="National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China">
<meta name="citation_publication_date" content="2025 May 30">
<meta name="citation_volume" content="84">
<meta name="citation_firstpage" content="103267">
<meta name="citation_doi" content="10.1016/j.eclinm.2025.103267">
<meta name="citation_pmid" content="40687742">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12273842/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12273842/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12273842/pdf/main.pdf">
<meta name="description" content="Chimeric antigen receptor (CAR)-T cell therapies are being tested in many ongoing trials against hematologic malignancies and solid tumors. The incidence and profile of treatment-related adverse events are necessary when moving to clinical practice. ...">
<meta name="og:title" content="Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Chimeric antigen receptor (CAR)-T cell therapies are being tested in many ongoing trials against hematologic malignancies and solid tumors. The incidence and profile of treatment-related adverse events are necessary when moving to clinical practice. ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12273842/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12273842">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1016/j.eclinm.2025.103267"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/main.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12273842%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12273842/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12273842/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12273842/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-eclinm.jpg" alt="eClinicalMedicine logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to eClinicalMedicine" title="Link to eClinicalMedicine" shape="default" href="https://www.thelancet.com/journals/eclinm/home" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">eClinicalMedicine</button></div>. 2025 May 30;84:103267. doi: <a href="https://doi.org/10.1016/j.eclinm.2025.103267" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1016/j.eclinm.2025.103267</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22eClinicalMedicine%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22eClinicalMedicine%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22eClinicalMedicine%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22eClinicalMedicine%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Youwen Zhu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Youwen Zhu</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Youwen Zhu</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Kun Liu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Kun Liu</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kun Liu</span></a>
</div>
</div>
<sup>a</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rosen%20ST%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Steven T Rosen</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Steven T Rosen</span></h3>
<div class="p">
<sup>b</sup>Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, CA, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rosen%20ST%22%5BAuthor%5D" class="usa-link"><span class="name western">Steven T Rosen</span></a>
</div>
</div>
<sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Wei Liu</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Wei Liu</span></h3>
<div class="p">
<sup>c</sup>Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div class="p">
<sup>d</sup>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wei Liu</span></a>
</div>
</div>
<sup>c,</sup><sup>d</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Hong Zhu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Hong Zhu</span></h3>
<div class="p">
<sup>a</sup>Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div class="p">
<sup>d</sup>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hong Zhu</span></a>
</div>
</div>
<sup>a,</sup><sup>d,</sup><sup>∗</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>a</sup>Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div id="aff2">
<sup>b</sup>Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, CA, USA</div>
<div id="aff3">
<sup>c</sup>Department of Hematology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div id="aff4">
<sup>d</sup>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China</div>
<div class="author-notes p"><div class="fn" id="cor1">
<sup>∗</sup><p class="display-inline">Corresponding author. Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, PR China. <span>zhuhong719@csu.edu.cn</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Oct 21; Revised 2025 May 6; Accepted 2025 May 7; Collection date 2025 Jun.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s)</div>
<p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12273842  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40687742/" class="usa-link">40687742</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abs0010"><h2>Summary</h2>
<section id="sec1_pmc"><h3 class="pmc_sec_title">Background</h3>
<p>Chimeric antigen receptor (CAR)-T cell therapies are being tested in many ongoing trials against hematologic malignancies and solid tumors. The incidence and profile of treatment-related adverse events are necessary when moving to clinical practice.</p></section><section id="sec2_pmc"><h3 class="pmc_sec_title">Methods</h3>
<p>Published clinical trials on CAR-T cell therapies were collected from PubMed, Embase, Cochrane, and Web of Science databases between January 1, 2010, and August 27, 2024, with an updated search up to May 1, 2025, to extract tabular data on treatment-related adverse events. A logit-transformed random effects model was used to calculate the incidence and 95% CI of all-grade and grade 3 or higher treatment-related adverse events, with inter-study heterogeneity primarily assessed by <em>I</em><sup><em>2</em></sup> statistics. Differences between different antigen-binder, co-stimulation, cancer types, and specific subgroups were also explored in detail. The study was registered on PROSPERO (ID, CRD42024596383).</p></section><section id="sec3_pmc"><h3 class="pmc_sec_title">Findings</h3>
<p>This systematic review and meta-analysis included 163 clinical trials involving 6342 patients. Of 4395 patients from 107 trials, 4312 (98.11% [95% CI, 97.65%–98.46%], <em>I</em><sup><em>2</em></sup> = 0.0%) had at least one adverse event of all-grade, and of 4248 patients from 103 trials, 3512 (82.67% [95% CI, 81.50%–83.78%], <em>I</em><sup><em>2</em></sup> = 82.8%) had at least one adverse event of grade 3 or higher. The most common all-grade adverse events and grade 3 or higher adverse events in hematological malignancies were cytokine release syndrome (81.50% [77.04%–85.43%]) and neutropenia (72.30% [62.94%–80.39%]), respectively. The most common all-grade adverse events and grade 3 or higher adverse events in solid tumors was lymphopenia (89.21% [45.31%–99.38%] and 51.96% [8.98%–92.87%]). Ciltacabtagene autoleucel was associated with a lower mean incidence of all-grade adverse events (Risk ratio [RR], 1.00; 95% CI, 0.99–1.01; Rank-score, 0.6341; <em>I</em><sup><em>2</em></sup> = 0.0%) and tisagenlecleucel were associated with lower grade 3 or higher adverse events (RR, 0.93; 95% CI, 0.86–1.02; Rank-score, 0.9738; <em>I</em><sup><em>2</em></sup> = 78.4%) compared with standard care and CAR T-cell therapies. Anti-CD19 CAR-T cells were associated with a lower mean incidence of grade 3 or higher adverse events compared with anti-BCMA CAR-T cells (RR, 0.93; 95% CI, 0.87–0.99; <em>I</em><sup><em>2</em></sup> = 78.4%). CAR-T cells containing 4-1BB costimulation had a lower incidence of grade 3 or higher adverse events than CAR-T cells containing CD28 costimulation (RR, 0.88; 95% CI, 0.81–0.95; <em>I</em><sup><em>2</em></sup> = 78.4%).</p></section><section id="sec4_pmc"><h3 class="pmc_sec_title">Interpretation</h3>
<p>Our study provides comprehensive data on adverse events associated with different CAR-T cell treatments, maps a complete toxicity profile, and provides an important reference for clinicians to select and manage anti-cancer therapies.</p></section><section id="sec5_pmc"><h3 class="pmc_sec_title">Funding</h3>
<p>This study was supported by the Changsha Natural Science Foundation of Hunan Provincial of China (Grant/Award Number: kq2208376 to HZ).</p></section><section id="kwrds0010" class="kwd-group"><p><strong>Keywords:</strong> Chimeric antigen receptor T-cell, Targeted, Oncology, Clinical trials, Treatment-related adverse events</p></section></section><hr class="headless">
<section class="bt xbox font-sm" id="dtbox1"><h2 class="obj_head">Research in context.</h2>
<section id="dtbox1sec1"><h3 class="pmc_sec_title">Evidence before this study</h3>
<p id="p0015">With the breakthrough of CAR-T cells in the treatment of hematologic malignancies, the focus of research is shifting to solid tumors, which also have initial therapeutic advantages. While the efficacy is significant, safety is also a major concern, and there is an urgent need to fully understand the toxic characteristics of CAR-T cell therapy. We searched Pubmed, Embase, Cochrane, and Web of Science databases for clinical trials investigating CAR-T cell therapy between January 1, 2010, and August 27, 2024, with an updated search up to May 1, 2025, with the search term “Chimeric Antigen Receptor-T”. “CAR-T”, “Cancer”, and “Clinical trials”. Eligible studies were limited to prospective trials published in English. If multiple articles from the same study had the most comprehensive adverse event table and fewer than 10 patients were included, the study was excluded.</p></section><section id="dtbox1sec2"><h3 class="pmc_sec_title">Added value of this study</h3>
<p id="p0020">In the present study, we conducted a systematic review and meta-analysis of 163 clinical trials with approximately 6342 participants. To our knowledge, our study provides the largest and most comprehensive meta-analysis of treatment-related adverse events based on CAR T-cell therapies. We report a comprehensive overview of common treatment-related adverse events and serious adverse events for CAR-T cells and detailed causes of treatment-related deaths. It is also discussed from many main aspects: different antigen-binder, co-stimulation, cancer types, and specific subgroups. It was found that CAR-T cell therapy had a high incidence of adverse events, and serious adverse events and treatment-related deaths were acceptable. There was a higher incidence of adverse events in hematologic malignancies, anti-BCMA CAR-T cells, and CAR-T cells with CD28 co-stimulation, patients with bulky tumors, prior more than second-line therapies, and previous hematopoietic stem cell transplantation.</p></section><section id="dtbox1sec3"><h3 class="pmc_sec_title">Implications of all the available evidence</h3>
<p id="p0025">Due to the increasing advantages of CAR-T cell therapies in recent years, different treatment strategies have different levels of adverse events. Understanding the toxicity profile is a clinical need, which also requires large clinical trials and real-world data support. Therefore, our study provides a comprehensive summary of CAR-T cell therapies, and an overview of treatment-related adverse events in clinical trials, and is intended to serve as a reference for clinicians in clinical practice and may supplement guidelines.</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="p0030">The emergence of chimeric antigen receptor (CAR)-T cell therapies has been among the most impactful breakthroughs in the immunotherapeutic management of cancer in recent years, providing an effective means of treating a range of hematological malignancies including leukemia, lymphoma, and multiple myeloma.<a href="#bib1" class="usa-link" aria-describedby="bib1">1</a>, <a href="#bib2" class="usa-link" aria-describedby="bib2">2</a>, <a href="#bib3" class="usa-link" aria-describedby="bib3">3</a>, <a href="#bib4" class="usa-link" aria-describedby="bib4">4</a> A growing number of clinical trials published in recent years have also yielded promising CAR-T treatment results in patients with various solid tumors including germ cell tumors, gastrointestinal cancers, and neuroblastomas,<a href="#bib5" class="usa-link" aria-describedby="bib5">5</a>, <a href="#bib6" class="usa-link" aria-describedby="bib6">6</a>, <a href="#bib7" class="usa-link" aria-describedby="bib7">7</a> underscoring the impactful nature of this innovative treatment strategy across cancer types. The expanding clinical uptake of CAR-T treatment approaches has led to their widespread testing for a wider range of indications across hundreds of studies published to date. However, there remains a pressing need for further studies aimed at better clarifying the most effective approaches to implementing CAR-T therapies based on a more thorough understanding of the attendant risks.</p>
<p id="p0035">The genetically engineered CAR transmembrane receptors are generally introduced into immune cell populations, predominantly T cells, through the use of viral vectors.<a href="#bib8" class="usa-link" aria-describedby="bib8"><sup>8</sup></a> There are four major domains that comprise the final CAR molecule, including an antigen-binding domain that most commonly consists of a single chain variable fragment from a monoclonal antibody (mAb-scFv), an IgG or CD8α/CD28-based hinge domain, a transmembrane (TM) domain, and an intracellular domain that can consist of co-stimulatory (most commonly 4-1BB and CD28) and signal transduction (predominantly CD3ζ) domains.<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a> CAR antigen specificity is the primary factor that determines the safety and efficacy profile of the resultant CAR-T cells.<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a> The tuning of CAR affinity, epitope locations, and the features of the hinge, TM, and signal domains can all improve CAR-T cell-mediated tumor recognition.<a href="#bib9" class="usa-link" aria-describedby="bib9"><sup>9</sup></a> The two most characteristic and common toxic reactions associated with CAR-T therapy are cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS). These disorders are mediated by activated T-cells and cytokines released by bystander immune cells (primarily IL-6) and activated by initial CAR-T/tumor target interactions.<a href="#bib10" class="usa-link" aria-describedby="bib10"><sup>10</sup></a> In solid tumors, the most prominent form of toxicity associated with CAR-T treatment consists of on-target extratemporal effects mediated by the recognition of the target antigens of the engineered CAR-T cells in off-tumor tissues. Upon target engagement, these CAR-T cells form immune synapses with the target cell that trigger the release of effector factors that ultimately lead to target cell killing.<a href="#bib11" class="usa-link" aria-describedby="bib11"><sup>11</sup></a></p>
<p id="p0040">To date, the U.S. Food and Drug Administration (FDA) has approved two CAR-T products targeting B cell maturation antigen (BCMA) (Abecma [idecabtagene vicleucel; ide-cel] and Carvykti [cabtagene autoleucel; cilta-cell]), as well as four targeting CD19 (Breyanzi [lisocabtagene maraleucel; iso-cel], Kymriah [tisagenlecleucel; tisa-cel], Tecartus [brexucabtagene autoleucel; brexu-cel], and Yescarta [axicabtagene ciloleuce; axi-cel]). Despite consistent evidence that these CAR-T therapies can provide promising efficacy when used for cancer treatment, their tolerability remains a topic of active concern to both patients and clinicians, particularly given the risk of severe, sometimes life-threatening adverse events. A few meta-analyses conducted to date have explored the clinical toxicity associated with CAR-T treatment, revealing relatively high incidence of CRS incidence and generally high adverse events incidence associated with both anti-CD19 and anti-BCMA CAR-T products.<a href="#bib12" class="usa-link" aria-describedby="bib12">12</a>, <a href="#bib13" class="usa-link" aria-describedby="bib13">13</a>, <a href="#bib14" class="usa-link" aria-describedby="bib14">14</a> However, most of these studies focused on the incidence of CRS and neurotoxicity associated with hematologic malignancies, and only one study looked at the incidence of non-CRS and neurotoxicity. In this study, all adverse events related to the treatment of hematologic malignancies and solid tumors were discussed in detail, with a particular focus on CRS and neurotoxicity. There remains a pressing need for quantitative analyses aimed at surveying different adverse events associated with a range of CAR-T therapies, providing a broader view of the full spectrum of treatment-related toxicity. Comprehensive toxicity profiles are vital to fully assess treatment-related risks to enable the more effective clinical application of these therapies.</p>
<p id="p0045">The goal of this study was to systematically explore the incidence and characteristics of all treatment-related adverse events associated with CAR-T therapies based on data published in clinical trials. These analyses included summaries of adverse events associated with different antigen-binding domains, co-stimulatory domains, and target tumor types, thus offering a detailed survey that can aid the appropriate selection of CAR-T regimens while addressing current gaps in the international guidelines for CAR-T therapy management. Data from large-scale phase III randomized controlled trials (RCTs) were further used to compare treatment-related adverse events incidence across drugs and domains.</p></section><section id="sec2"><h2 class="pmc_sec_title">Methods</h2>
<p id="p0050">This meta-analysis was conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, which was registered on PROSPERO (ID, CRD42024596383).<a href="#bib15" class="usa-link" aria-describedby="bib15"><sup>15</sup></a></p>
<section id="sec2.1"><h3 class="pmc_sec_title">Search strategy and study selection</h3>
<p id="p0055">The PubMed, Cochrane, Embase, and Web of Science databases were searched for relevant articles published between January 1, 2010, and August 27, 2024, with an updated search up to May 1, 2025, using the following search terms: “Chimeric antigen receptor-T”, “CAR-T”, “Cancer”, and “Clinical Trials” (<a href="#appsec1" class="usa-link">Supplementary Table S1</a>). Studies were eligible for inclusion if they<a href="#bib1" class="usa-link" aria-describedby="bib1"><sup>1</sup></a> focused on cancer patients undergoing CAR-T treatment,<a href="#bib2" class="usa-link" aria-describedby="bib2"><sup>2</sup></a> provided details and supporting tabular data related to treatment-related adverse events incidence,<a href="#bib3" class="usa-link" aria-describedby="bib3"><sup>3</sup></a> were prospective clinical trials published before August 27, 2024, and<a href="#bib4" class="usa-link" aria-describedby="bib4"><sup>4</sup></a> were published in English. Studies were excluded if<a href="#bib1" class="usa-link" aria-describedby="bib1"><sup>1</sup></a> non-cancer patients were included,<a href="#bib2" class="usa-link" aria-describedby="bib2"><sup>2</sup></a> the primary treatment did not consist of CAR-T cell therapy,<a href="#bib3" class="usa-link" aria-describedby="bib3"><sup>3</sup></a> the studies were not prospective clinical trials,<a href="#bib4" class="usa-link" aria-describedby="bib4"><sup>4</sup></a> they were meeting abstracts, or<a href="#bib5" class="usa-link" aria-describedby="bib5"><sup>5</sup></a> they enrolled fewer than 10 patients. If multiple articles were associated with the same study, the most comprehensive dataset with the most complete adverse events-related data or the most recent study was retained for analysis.</p></section><section id="sec2.2"><h3 class="pmc_sec_title">Data extraction</h3>
<p id="p0060">Two investigators (YW Zhu and K Liu) independently completed the process of study selection, with a third investigator (H Zhu) helping to resolve any discrepancies. These investigators extracted author names, publication year, trial name, trial stage, cancer type, CAR-T name, and structural features, the number of patients that underwent CAR-T treatment, the number of adverse events, and associated references, compiling these in an independent table (<a href="#appsec1" class="usa-link">Supplementary Table S2</a>). Safety data were additionally extracted for treatment-related adverse events of all grades (Common Terminology Standard for Adverse Events [CTCAE] grade 1 to 5), serious treatment-related adverse events (serious threat to the patient's health or death), treatment-related mortality (CTCAE grade 5), and second primary malignancy. Adverse events coding was performed as per the Medical Dictionary of Regulatory Activities (MedDRA).</p></section><section id="sec2.3"><h3 class="pmc_sec_title">Statistical analyses</h3>
<p id="p0065">Overall adverse events incidence and adverse events profiles were analyzed based on the number of events relative to the number of patients, with logit-transformation random-effects models being used to compute the final risk and corresponding 95% confidence intervals (CIs).<a href="#bib16" class="usa-link" aria-describedby="bib16"><sup>16</sup></a> These models were fitted with restricted maximum likelihood estimates and the addition of 0.5, a simple form of Firth penalization, for each cell.<a href="#bib16" class="usa-link" aria-describedby="bib16"><sup>16</sup></a> In the case that different clinical trials may report incomplete adverse events at different specific cutoff thresholds, cumulative binomial probabilities were used for left-censoring adverse events to maintain the possibility of consistent parameter estimation by Bayesian meta-analysis of adverse drug effects with censored data (MAGEC) modeling framework.<a href="#bib17" class="usa-link" aria-describedby="bib17">17</a>, <a href="#bib18" class="usa-link" aria-describedby="bib18">18</a>, <a href="#bib19" class="usa-link" aria-describedby="bib19">19</a> The primary aggregate measures for this study were the incidence and associated profiles for all-grade and grade 3 or higher adverse events. Treatment-related mortality profiles were established by comparing the number of deaths to the total number of treatment patients. Given the complex structural features of CAR-T cells, subgroup analyses for adverse events incidence were performed for different CAR-T cell antigen targets (&gt;20 in total) and co-stimulatory domains (4-1BB and CD28). Adverse event incidence were also established for different types of cancers (hematologic malignancies and solid tumors). In addition, factors that might influence the incidence of adverse events were also explored (tumors bulk, number of lines of prior therapy, prior autologous or allogeneic stem cell transplantation [SCT], baseline lactate dehydrogenase [LDH], and baseline C-reactive protein [CRP]). The one-way ANOVAs were used to detect differences in incidence between groups in these subgroup analyses, with <em>P</em> &lt; 0.05 being indicative of significant differences. Before this, Shapiro–Wilk W and Levene's tests are required to determine whether normality and homogeneity of variance are satisfied. If these hypotheses are not valid, the non-parametric test is performed (Kruskal–Wallis H-test [<em>P</em> ≤ 0.050 is considered a significant difference between groups]). After multiple testing adjustments, the Bonferroni correction method was used.</p>
<p id="p0070">Data from corresponding RCTs were extracted and used to perform indirect comparisons of the safety profiles of five different CAR-T regimens, standard of care, anti-CD19 CAR-T therapies, anti-BCMA CAR-T therapies, and CAR-T therapies with differing co-stimulatory domains. A frequentist network meta-analysis method was conducted with the corresponding effect model to summarize risk ratios (RRs) and 95% CIs when assessing safety, together with rank-scores (<em>p</em>-scores), with higher scores being indicative of a better safety profile.<a href="#bib20" class="usa-link" aria-describedby="bib20"><sup>20</sup></a><sup>,</sup><a href="#bib21" class="usa-link" aria-describedby="bib21"><sup>21</sup></a> An <em>I</em><sup><em>2</em></sup> statistic &gt;50% was considered indicative of significant heterogeneity (random-effects model) and the source of heterogeneity should be evaluated using meta-regression analysis by STATA (v 18.0) with the <em>metareg</em> packages (the Restricted Maximum Likelihood [REML] algorithm).<a href="#bib22" class="usa-link" aria-describedby="bib22"><sup>22</sup></a> Cochrane collaborative guidelines were used to assess the risk of bias for clinical trials.<a href="#bib23" class="usa-link" aria-describedby="bib23"><sup>23</sup></a> Analyses of the risk of bias were performed using funnel plots, with symmetry being indicative of the absence of bias, and Egger's tests, with <em>P</em> &gt; 0.050 being indicative of the absence of publication bias.<a href="#bib24" class="usa-link" aria-describedby="bib24"><sup>24</sup></a><sup>,</sup><a href="#bib25" class="usa-link" aria-describedby="bib25"><sup>25</sup></a> R (v 4.4.0) with the <em>meta and netmeta</em> packages and Shiny-MAGEC were used to analyze data.<a href="#bib26" class="usa-link" aria-describedby="bib26"><sup>26</sup></a></p></section><section id="sec2.4"><h3 class="pmc_sec_title">Ethics statement</h3>
<p id="p0075">This protocol was not submitted for ethical review because it was a systematic review and meta-analysis of CAR-T treatment-related adverse events, not patients or personal health information.</p></section><section id="sec2.5"><h3 class="pmc_sec_title">Role of funding source</h3>
<p id="p0080">The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.</p></section></section><section id="sec3"><h2 class="pmc_sec_title">Results</h2>
<section id="sec3.1"><h3 class="pmc_sec_title">Eligible trials and characteristics</h3>
<p id="p0085">The selected search strategy returned 1104 records, ultimately leading to the inclusion of 163 trials enrolling 6342 patients with various cancer types in the present meta-analysis (<a href="#fig1" class="usa-link">Fig. 1</a> and <a href="#appsec1" class="usa-link">Supplementary Table S2</a>). All trials were evaluated for risk of bias (<a href="#appsec1" class="usa-link">Supplementary Table S3</a>). In total, 25 CAR-T therapy types targeting different tumor-associated antigens were identified among these trials, including therapies targeting CD19 (n = 79), BCMA (n = 18), mixed targets (n = 18), CD22 (n = 5), CD30 (n = 5), disialoganglioside (GD2, n = 4), human epidermal growth factor receptor 2 (HER-2, n = 4), CD7 (n = 3), class C group 5 member D (GPRC5D, n = 3), epidermal growth factor receptor (EGFR, n = 3), mesothelin (n = 3), carcinoembryonic antigen (CEA, n = 2), claudin18.2 (CLND18.2, n = 2), natural killer group 2D (NKG2D, n = 2), carboxyanhydrase-IX (CAIX, n = 1), CD20 (n = 1), CD70 (n = 1), CD133 (n = 1), C-type lectin-like molecule 1 (CLL-1, n = 1), glypican-3 (GPC3, n = 1), human papillomavirus (HPV, n = 1), interleukin-13 receptor alpha 2 (IL-13Rα2, n = 1), prostate stem cell antigen (PSCA, n = 1), claudin 6 (CLDN6, n = 1), prostate-specific membrane antigen (PSMA, n = 1), and tumor-associated glycoprotein-72 (TAG-72, n = 1). These trials enrolled patients undergoing treatment for lymphoma (n = 49), multiple cancers (n = 46), leukemia (n = 45), gastrointestinal cancers (n = 9), neurological cancers (n = 5), genitourinary cancers (n = 4), sarcomas (n = 2), epithelial cancers (n = 1), lung cancer (n = 1), and pleural mesothelioma (n = 1).</p>
<figure class="fig xbox font-sm" id="fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12273842_gr1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7d/12273842/a1ab8d9b6316/gr1.jpg" loading="lazy" height="665" width="787" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Study selection process.</p></figcaption></figure></section><section id="sec3.2"><h3 class="pmc_sec_title">Overall incidence of treatment-related adverse events</h3>
<p id="p0090">At least one all-grade adverse event was reported for 4312 of 4395 patients (98.11% [95% CI, 97.65%–98.46%]; <em>I</em><sup>2</sup> = 0%) across 107 trials, while 3512 of 4248 patients (82.67% [95% CI, 81.50%–83.78%]; <em>I</em><sup><em>2</em></sup> = 82.8%) across 103 trials experienced at least one grade 3 or higher adverse events. Of 4312 hematologic malignancies, 4031 reported at least one all-grade adverse event (98.40% [97.96%–98.74%]), and among 3217 of 3820 patients (84.21% [83.01%–85.33%]) experienced at least one grade 3 or higher adverse event. When overall adverse events incidence was summarized by CAR-T antigen-binding domain, the CAR-T therapy types most commonly associated with all-grade adverse events and grade 3 or higher adverse events were anti-BCMA (99.78% [99.23%–99.93%]) and anti-GPRC5D (99.18% [88.21%–99.95%]) therapies, respectively (<a href="#fig2" class="usa-link">Fig. 2</a>).</p>
<figure class="fig xbox font-sm" id="fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12273842_gr2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7d/12273842/f3f87f3fa85b/gr2.jpg" loading="lazy" height="1118" width="782" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The overall incidence of adverse events in different antigen-binder classes. Note: A. All-grade adverse event; B. Grade 3 or higher adverse events. Abbreviations: BCMA, B cell maturation antigen; CLND18.2, Claudin18.2; GPRC5D, class C group 5 member D; HER2, Human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; NKG2D, the natural killer group 2D; CEACAM5, carcinoembryonic antigen; GPC3, Glypican-3; HPV, Human papillomavirus; CEA, carcinoembryonic antigen; CLL-1, C-type lectin-like molecule 1; GD2, disialoganglioside; CLDN6, The oncofetal antigen claudin 6; IL-13Rα2, interleukin-13 receptor alpha 2.</p></figcaption></figure><p id="p0095">Of 364 solid tumours, 345 reported at least one all-grade adverse event (94.66% [91.82%–96.55%]), and among 295 of 428 patients (68.88% [64.34%–73.09%]) experienced at least one grade 3 or higher adverse event. When overall adverse events incidence was summarized by CAR-T antigen-binding domain, the CAR-T therapy types most commonly associated with all-grade adverse events and grade 3 or higher adverse events were anti-CLND18.2 (99.59% [93.84%–99.97%]) and anti-CLND18.2 (99.59% [93.84%–99.97%]) therapies, respectively (<a href="#fig2" class="usa-link">Fig. 2</a>).</p>
<p id="p0100">Over 150 different treatment-related adverse event types were reported across the 163 trials included in this study. To focus on the adverse events with the greatest clinical relevance, those reported in fewer than three studies were excluded from the analysis and 116 adverse events were included eventually. In patients with hematologic malignancies, the most commonly reported all-grade adverse events included CRS (81.50% [77.04%–85.43%]), neutropenia (76.89% [68.28%–84.13%]), and fever/pyrexia (74.39% [64.53%–82.65%]). In patients with hematologic malignancies, the most commonly reported grade 3 or higher adverse events included neutropenia (72.30% [62.94%–80.39%]), lymphopenia (49.44% [26.42%–73.76%]), and leukopenia (42.20% [24.79%–59.96%]) (<a href="#fig3" class="usa-link">Fig. 3</a>). In patients with solid tumours, the most commonly reported all-grade and grade 3 or higher adverse events included lymphopenia (89.21% [45.31%–99.38%] and 51.96% [8.98%–92.87%]), leukopenia (88.18% [1.40%–99.99%] and 42.28% [11.01%–79.86%]), and neutropenia (66.60% [31.67%–91.13%] and 24.55% [0.81%–77.83%]) (<a href="#fig3" class="usa-link">Fig. 3</a>).</p>
<figure class="fig xbox font-sm" id="fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12273842_gr3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7d/12273842/d553a5a2737a/gr3.jpg" loading="lazy" height="437" width="738" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Incidences of the most common adverse events. Note: A. All-grade adverse events in hematological malignancies; B. Grade 3 or higher adverse events in hematological malignancies; C. All-grade adverse events in solid tumors; D. Grade 3 or higher adverse events in solid tumors. Abbreviations: n/N, reported events/corresponding total; CRS, Cytokine release syndrome; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; ICANS, Immune cell-associated neurotoxicity syndrome; APTT, Activated partial thromboplastin time; GGT, Gamma-glutamyltransferase.</p></figcaption></figure><p id="p0105">In addition, generic CAR-T-related adverse events were also explored in greater detail (<a href="#fig4" class="usa-link">Fig. 4</a>). In patients with hematologic malignancies, the incidence of all-grade and grade 3 or higher CRS was 81.50% (77.04%–85.43%) and 9.78% (7.84%–11.86%), respectively; the incidence of all-grade and grade 3 or higher ICANS was 18.76% (14.38%–23.75%) and 4.84% (3.32%–6.65%), respectively; the incidence of all-grade and grade 3 or higher infection was 25.35% (16.03%–36.13%) and 12.26% (9.22%–15.36%), respectively. In patients with solid tumours, the incidence of all-grade and grade 3 or higher CRS was 54.27% (30.40%–75.83%) and 1.79% (0.19%–6.03%), respectively; the incidence of all-grade and grade 3 or higher ICANS was 1.86% (0.01%–15.31%) and 0.00% (0.00%–0.00%), respectively; the incidence of all-grade and grade 3 or higher infection was 4.09% (0.03%–12.85%) and 1.58% (0.01%–15.26%), respectively. In addition to the general adverse event analysis of the CAR-T products that have been produced, the results showed satricabtagene autoleucel (94.79% [22.88%–99.92%]) and brexucabtagene autoleucel (17.24% [5.10%–44.78%]) had higher all-grade and grade 3 or higher CRS; Axicabtagene ciloleucel (77.09% [47.00%–94.84%]) and brexucabtagene autoleucel (31.44% [21.75%–42.86%]) have higher all-grade and grade 3 or higher ICANS; Tisagenlecleucel (43.54% [0.19%–99.80%]) and idecabtagene vicleucel (16.91% [0.16%–68.50%]) had higher all-grade and grade 3 or higher infection (<a href="#fig4" class="usa-link">Fig. 4</a>).</p>
<figure class="fig xbox font-sm" id="fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12273842_gr4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7d/12273842/463da596e8c4/gr4.jpg" loading="lazy" height="689" width="738" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Generic CAR-T Toxicities. Note: A. All-grade CRS; B. Grade 3 or higher CRS; C. All-grade ICANS; D. Grade 3 or higher ICANS; E. All-grade infection; F. Grade 3 or higher infection. Abbreviations: n/N, reported events/corresponding total; CRS, Cytokine release syndrome; ICANS, Immune cell-associated neurotoxicity syndrome.</p></figcaption></figure></section><section id="sec3.3"><h3 class="pmc_sec_title">Incidence of treatment-related serious adverse events, death, and second primary malignancy</h3>
<p id="p0110">In 27 trials enrolling 1418 patients, 690 of these patients (48.66% [46.06%–51.26%]; <em>I</em><sup><em>2</em></sup> = 71.6%) experienced serious treatment-related adverse events. Of these adverse events, the most commonly reported were infection (17.33% [13.61%–21.80%]), prolonged cytopenia (16.67% [5.47%–40.86%]), pyrexia (10.00% [8.24%–12.09%]), tumor lysis syndrome (8.70% [2.18%–28.88%]), hypotension (8.39% [6.09%–11.47%]), and CRS (8.19% [6.28%–10.61%]) (<a href="#appsec1" class="usa-link">Supplementary Table S4</a> and <a href="#appsec1" class="usa-link">Figure S1</a>).</p>
<p id="p0115">In 99 trials enrolling 4574 patients, 146 of these patients (3.19% [2.72%–3.74%]; <em>I</em><sup><em>2</em></sup> = 0%) experienced treatment-related mortality. The most commonly reported causes of treatment-related death included infections (n = 50 [34.3%]), CRS (n = 32 [21.9%]), pneumonia (12 [8.2%]), multisystem organ failure (6 [4.1%]), and cerebral hemorrhage (5 [3.4%]) (<a href="#tbl1" class="usa-link">Table 1</a>).</p>
<section class="tw xbox font-sm" id="tbl1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Causes of 146 treatment-related deaths of CAR-T cell therapies.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th colspan="1" rowspan="1">Cause of death</th>
<th colspan="1" rowspan="1">CAR-T cell therapy (N = 4574)<br>Patients-no. (%)</th>
</tr></thead>
<tbody>
<tr>
<td colspan="1" rowspan="1"><strong>Overall</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>146 (3.2)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Immune system disorders</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>36 (24.7)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Cytokine release syndrome</td>
<td align="center" colspan="1" rowspan="1">32 (21.9)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Immune cell-associated neurotoxicity syndrome</td>
<td align="center" colspan="1" rowspan="1">3 (2.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Haemophagocytic lymphohistiocytosis</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Infections and infestations</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>50 (34.3)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Sepsis</td>
<td align="center" colspan="1" rowspan="1">17 (11.6)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Bacteremia</td>
<td align="center" colspan="1" rowspan="1">5 (3.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Septic shock</td>
<td align="center" colspan="1" rowspan="1">5 (3.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Infection (Unknown<a href="#tbl1fna" class="usa-link"><sup>a</sup></a>)</td>
<td align="center" colspan="1" rowspan="1">5 (3.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Aspergillosis</em>
</td>
<td align="center" colspan="1" rowspan="1">3 (2.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Candidemia</em>
</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Klebsiella</em>
</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Septicaemia</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Pulmonary infection</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Cytomegalovirus</em>
</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Escherichia coli</em>
</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Herpes simplex virus</em>
</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Mucormycosis</em>
</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> <em>Staphylococcus</em>
</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Intestinal infection</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Perineal infection</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Respiratory</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>24 (16.4)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Pneumonia</td>
<td align="center" colspan="1" rowspan="1">12 (8.2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Pulmonary hemorrhage</td>
<td align="center" colspan="1" rowspan="1">4 (2.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Bronchopneumonia</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Respiratory failure</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Acute respiratory distress syndrome</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Diffuse alveolar damage</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Hypoxia</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Lung abscess</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Neurologic</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>10 (6.9)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Cerebral hemorrhage</td>
<td align="center" colspan="1" rowspan="1">5 (3.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Encephalopathy syndrome</td>
<td align="center" colspan="1" rowspan="1">3 (2.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Brain herniation</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Progressive multifocal leukoencephalopathy</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Gastrointestinal</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>8 (5.5)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Gastrointestinal hemorrhage</td>
<td align="center" colspan="1" rowspan="1">3 (2.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Hepatic failure</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Alimentary tract hemorrhage</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Mesenteric infarction</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Pseudomembranous colitis</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Cardiovascular</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>7 (4.8)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Cardiac arrest</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Refractory hypotension</td>
<td align="center" colspan="1" rowspan="1">2 (1.4)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Cardiac arrhythmia</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Cardiomyopathy</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Veno-occlusive disease</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Hematologic</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>3 (2.1)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Neutropenia</td>
<td align="center" colspan="1" rowspan="1">3 (2.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Other</strong></td>
<td align="center" colspan="1" rowspan="1"><strong>8 (5.5)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Multisystem organ failure</td>
<td align="center" colspan="1" rowspan="1">6 (4.1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Therapy-related acute myeloid leukaemia</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> Therapy-related myelodysplastic syndrome</td>
<td align="center" colspan="1" rowspan="1">1 (0.7)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tbl1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="tbl1fna">
<sup>a</sup><p class="display-inline" id="ntpara0010">No details were given on the species of infected organism.</p>
</div></div></section><p id="p0120">In 16 trials enrolling 1677 patients, 127 of these patients (7.57% [6.40%–8.94%]; <em>I</em><sup><em>2</em></sup> = 56.2%) experienced second primary malignancy. The most commonly reported second primary malignancy was myelodysplastic syndrome (n = 30 [1.8%]), Basal cell carcinoma (n = 15 [9.0%]), squamous cell carcinoma (14 [8.4%]), Acute myeloid leukemia (12 [7.2%]), and malignant melanoma (8 [4.8%]) (<a href="#appsec1" class="usa-link">Supplementary Table S5</a>).</p></section><section id="sec3.4"><h3 class="pmc_sec_title">Subgroup analyses of incidence of treatment-related adverse events</h3>
<p id="p0125">Next, the overall incidence of adverse events and associated adverse events profiles were evaluated for these 25 different CAR-T therapies across 163 clinical trials based on their target antigens (<a href="#fig2" class="usa-link">Fig. 2</a> and <a href="#appsec1" class="usa-link">Supplementary Figure S2</a>). The most commonly reported all-grade adverse events associated with anti-CD19 CAR-T therapies included CRS (77.98% [76.39%–79.50%]), pyrexia (67.11% [64.60%–69.52%]), and neutropenia (57.10% [54.48%–59.68%]), while the most common grade 3 or higher adverse events were neutropenia (48.70% [46.20%–51.20%]), lymphopenia (36.11% [31.88%–40.57%]), and anaemia (31.51% [29.09%–34.04%]). Among patients who underwent anti-BCMA CAR-T therapy, the most commonly reported all-grade adverse events included white blood cell (WBC) count decreased (86.21% [68.51%–94.73%]), neutropenia (86.15% [83.88%–88.15%]), and CRS (81.16% [78.72%–83.38%]), while the most commonly reported grade 3 or higher adverse events included WBC count decreased (88.00% [68.70%–96.08%]), neutropenia (84.15% [81.80%–86.24%]), and prolonged activated partial thromboplastin time (APTT) (54.55% [43.38%–65.27%]). Treatment-related adverse events for other CAR-T antigen-binding domains are summarized in <a href="#appsec1" class="usa-link">Table S6</a> and <a href="#appsec1" class="usa-link">Figure S2</a> in the supplementary materials.</p>
<p id="p0130">When focusing on adverse events associated with CAR-T patients with 4-1BB and CD28 co-stimulatory domains, 4067 of 4141 patients (98.21% [97.76%–98.57%]); <em>I</em><sup><em>2</em></sup> = 0%) across 99 studies experienced at least one all-grade adverse event, while 3335 of 4015 patients (83.06% [81.87%–84.19%]); <em>I</em><sup><em>2</em></sup> = 82.9%) across 96 studies experienced at least one grade 3 or higher adverse events. Next, the adverse events profiles of CAR-T patients with 4-1BB and CD28 co-stimulatory domains were explored in greater detail, pooling the adverse events profiles from 105 (4059 patients) and 45 (1856 patients) trials, respectively (<a href="#appsec1" class="usa-link">Supplementary Table S7</a>). Among patients who underwent CAR-T treatment with 4-1BB co-stimulation, the most commonly reported all-grade and grade 3 or higher adverse events was CRS (79.13% [73.80%–83.95%] and neutropenia (68.15% [66.38%–69.86%]). In addition, the incidence of all-grade and grade 3 or higher CRS was 79.13% (73.80%–83.95%) and 8.91% (6.60%–11.49%), respectively; the incidence of all-grade and grade 3 or higher ICANS was 15.26% (11.79%–19.13%) and 3.31% (2.09%–4.83%), respectively; the incidence of all-grade and grade 3 or higher infection was 45.14% (32.49%–58.72%) and 15.24% (11.11%–19.96%), respectively (<a href="#fig4" class="usa-link">Fig. 4</a>). Among patients who underwent CAR-T treatment with CD28 co-stimulation, the most commonly reported all-grade adverse events were pyrexia (85.27% [82.96%–87.31%]) and lymphopenia (71.09% [66.78%–75.05%]), respectively. The incidence of all-grade and grade 3 or higher CRS was 81.07% (69.62%–89.08%) and 9.62% (6.45%–13.28%), respectively; the incidence of all-grade and grade 3 or higher ICANS was 31.78% (14.37%–53.46%) and 8.30% (3.55%–14.78%), respectively; the incidence of all-grade and grade 3 or higher infection was 21.26% (5.12%–51.93%) and 9.69% (3.01%–20.61%), respectively (<a href="#fig4" class="usa-link">Fig. 4</a>). The incidence of generic CAR-T-related adverse events of CD28 and 41BB in different cancer types was also shown in <a href="#fig4" class="usa-link">Fig. 4</a>.</p>
<p id="p0135">In addition, factors that might influence the incidence of adverse events were also explored (tumors bulk [105 studies], number of lines of prior therapy [111 studies], prior autologous or allogeneic SCT [113 studies], baseline LDH [38 studies], and baseline CRP [38 studies]). All-grade Adverse events in patients with bulky tumors (98.48% [97.96%–98.87%]), prior first-line therapy (99.25% [97.87%–99.74%]), prior autologous or allogeneic SCT (94.93% [94.09%–95.66%]), baseline normal LDH (97.63% [96.29%–98.49%]), and baseline normal CRP (99.84% [97.48%–99.99%]); Grade 3 or higher adverse events in patients with bulky tumors (81.71% [80.24%–83.10%]), more than second-line of prior therapy (84.30% [83.10%–85.44%]), prior autologous or allogeneic SCT (80.66% [79.16%–82.08%]), baseline normal LDH (83.87% [81.16%–86.26%]), and baseline normal CRP (92.77% [89.30%–95.17%]) (<a href="#fig5" class="usa-link">Fig. 5</a>). In multivariable meta-regression analyses, factors associated with a higher incidence of grade 3 or higher AEs included hematologic malignancies, more than second-line of prior therapy, and bulky tumors; Factors associated with a higher incidence of CRS include hematologic malignancies and bulky tumors; And factors associated with a lower incidence of ICANS included CAR-T with 4-1BB co-stimulatory and anti-CD19 (<a href="#appsec1" class="usa-link">Supplementary Table S8</a> and <a href="#appsec1" class="usa-link">Figure S3</a>). The highest mean all-grade adverse events (ANOVA, <em>P</em> = 0.0014) and grade 3 or higher adverse events (ANOVA, <em>P</em> = 0.043) incidence were evident in multiple myeloma (99.71% [99.19%–99.90%] and 92.33% [90.71%–93.68%]). ANOVA and nonparametric tests found significant differences in the incidence of adverse events across cancer type, antigen-binder, number of lines of prior therapy, tumors bulk, and prior autologous or allogeneic SCT (<a href="#appsec1" class="usa-link">Supplementary Table S9</a>).</p>
<figure class="fig xbox font-sm" id="fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12273842_gr5.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed7d/12273842/221e9b34845f/gr5.jpg" loading="lazy" height="470" width="738" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Incidences of adverse events in subgroups. Note: A. All-grade adverse events; B. Grade 3 or higher adverse events. Abbreviations: n/N, reported events/corresponding total; SCT, stem cell transplantation; CRP, C-reactive protein; LDH. lactate dehydrogenase.</p></figcaption></figure></section><section id="sec3.5"><h3 class="pmc_sec_title">Indirect comparisons of treatment-related adverse events</h3>
<p id="p0140">Using five RCTs enrolling 882 patients, indirect comparisons of treatment-related adverse events were performed focusing on different CAR-T therapies (5 types), standard of care (platinum-based chemoimmunotherapy regimens), target antigens (2 types), and co-stimulatory domains (2 types). It was found to be transitive and similar based on the baseline features of RCTs, and therefore comparable between treatments (<a href="#appsec1" class="usa-link">Supplementary Figure S4</a> and <a href="#appsec1" class="usa-link">Table S10</a>). Among the approved drugs included in this analysis, ciltacabtagene autoleucel was associated with a lower mean all-grade adverse event incidence (RR, 1.00 [0.99–1.01]; <em>p-score</em> = 0.6341) while tsagenlecleucel was associated with a lower mean incidence of grade 3 or higher adverse events (0.93 [0.86–1.02]; <em>p-score</em> = 0.9738) relative to standard therapies. With respect to antigen targets, anti-CD19 CAR-T therapies were associated with lower mean incidence for both all-grade (0.99 [0.98–1.01]; <em>p-score</em> = 0.4646) and grade 3 or higher adverse events (0.93 [0.87–0.99]; <em>p-score</em> = 0.6097) relative to anti-BCMA CAR-T therapies. As to the CAR-T costimulatory domains, 4-1BB CAR-T cells were associated with lower incidence of all-grade (0.99 [0.98–1.01]; <em>p-score</em> = 0.3714) and grade 3 or higher adverse events (0.88 [0.81–0.95]; <em>p-score</em> = 0.9995) relative to treatment outcomes when using CD28 CAR-T cells (<a href="#appsec1" class="usa-link">Supplementary Table S11</a>).</p></section><section id="sec3.6"><h3 class="pmc_sec_title">Study heterogeneity and publication bias</h3>
<p id="p0145">The sources of heterogeneity found by meta-regression analysis were detailed in <a href="#appsec1" class="usa-link">Supplementary Table S8</a>. Study heterogeneity was defined by an <em>I</em><sup><em>2</em></sup> statistic was &gt;50% and the Cochran <em>Q</em> test <em>P</em>-value. No heterogeneity was observed concerning all-grade treatment-related adverse events (<em>I</em><sup><em>2</em></sup>, 0.0%; <em>P-</em>value range, 0.66–1.0), grade 3 or higher treatment-related in the CRP group (<em>I</em><sup><em>2</em></sup>, 0.0%; <em>P-</em>value, 0.61), or treatment-related death (<em>I</em><sup><em>2</em></sup>, 0.0%; <em>P-</em>value, 0.97) among the studies included here, while varying levels of heterogeneity were observed for grade 3 or higher treatment-related (<em>I</em><sup><em>2</em></sup>, range, 65.3%–89.2%; <em>P-</em>value, &lt;0.0001), serious adverse events (<em>I</em><sup><em>2</em></sup>, 71.6%; <em>P-</em>value, &lt;0.0001), and second primary malignancy (<em>I</em><sup><em>2</em></sup>, 56.2%; <em>P-</em>value, 0.0031) (<a href="#appsec1" class="usa-link">Supplementary Table S12</a>). No significant publication bias was detected in this study, as evidenced by a funnel plot (roughly symmetric) and Egger's test (<em>P</em> &gt; 0.05) (<a href="#appsec1" class="usa-link">Supplementary Table S11</a> and <a href="#appsec1" class="usa-link">Figure S5</a>).</p></section></section><section id="sec4"><h2 class="pmc_sec_title">Discussion</h2>
<p id="p0150">CAR-T therapies have recently emerged as promising anticancer treatment strategies that have been approved for the treatment of hematologic malignancies under various national guidelines. This initial success has prompted further exploration of the value of CAR-T therapies for non-hematological malignancies, and there have been a growing number of clinical trials focused on this topic and a range of different cancer-specific targets. However, the lack of safety data for these therapies remains a persistent detriment to their wider uptake. The present study represents the largest and most comprehensive systematic review and meta-analysis of CAR-T treatment-related adverse events to date, compiling research data from 163 published trials. Previously published meta-analyses have included far fewer studies (80 or less) and were primarily focused on particular adverse events including CRS, neurological symptoms, cardiovascular toxicity, and hematological toxicity.<a href="#bib12" class="usa-link" aria-describedby="bib12">12</a>, <a href="#bib13" class="usa-link" aria-describedby="bib13">13</a>, <a href="#bib14" class="usa-link" aria-describedby="bib14">14</a><sup>,</sup><a href="#bib27" class="usa-link" aria-describedby="bib27"><sup>27</sup></a> These studies also noted different degrees of concern for different targets when assessing CAR-T treatment-related adverse events, but did not conduct in-depth analyses of solid tumors or co-stimulatory domains. Comprehensive analyses of all potential treatment-related adverse events commonly encountered in the course of CAR-T therapy are vital to provide clinicians with a valuable reference. A global profile of CAR-T-related adverse event incidence will provide complementary support for the formulation of international guidelines aimed at managing these complications, in addition to informing clinical practice.</p>
<p id="p0155">Several factors should be considered when obtaining informed consent from patients undergoing CAR-T therapy, and careful monitoring together with early recognition of adverse events-related signs and symptoms can aid in the post-treatment care of these patients. In this meta-analysis, CAR-T therapies were associated with a high incidence of treatment-related adverse events, with 98.10% and 82.67% of patients respectively experiencing all-grade and grade 3 or higher adverse events. Notably, CRS was the most common all-grade adverse event (79.659%) and the most common grade 3 or higher immune-related adverse event (8.94%). CRS also consistently emerged as the second most common serious (approximately 3.6% chance) and fatal (approximately 0.7% chance) events, which need to be disclosed to patients. The second most common immune-related adverse event of any grade was ICANS, impacting approximately 3 of every 10 CAR-T patients, while HLH and ICAS were the second most commonly diagnosed grade 3 or higher adverse events, affecting roughly 1 in 10 patients. However, patients were less likely to suffer serious or fatal outcomes associated with these adverse events. However, the overall incidence of CRS and ICANS was found to be significantly higher in hematologic malignancies and with CD28 co-stimulation CAR-T therapies, further suggesting that the management of hematologic malignancies and the use of different co-stimulation of CAR-T should be carefully considered and guided. Other common treatment-related adverse events were also observed in this patient population, including various hematological toxicities, coagulatory dysfunction, cardiovascular disease, infections, liver/kidney dysfunction, gastrointestinal function disorder, and electrolyte imbalances. Some of these adverse events were notably associated with specific CAR-T targets. For instance, electrogram abnormalities and hepatic toxicity were more common in patients undergoing anti-CD19 CAR-T treatment, while infection and coagulatory dysfunction were more closely associated with anti-BCMA CAR-T therapies. Hepatic toxicities were more common among patients undergoing anti-CD20, anti-CLDN6, anti-CLND18.2, and anti-CAIX CAR-T treatment, whereas cardiovascular toxicity was most commonly associated with anti-CD7 CAR-T therapy, and gastrotoxicity was a more common complication of anti-CEA, anti-HER2, anti-CD22, and anti-CD30 CAR-T therapies. Anti-EGFR CAR-T treatment was more commonly linked to systemic edema and oral diseases, while infection was more common in patients being treated with anti-CD70 and anti-GCP3 CAR-T regimens. Neurotoxicity was most commonly associated with anti-GD2 and anti-NKG2D CAR-T treatment, while nail changes were most closely associated with anti-GPRC5D CAR-T treatment, and dermal toxicity was reported most often for anti-GD2, anti-PSCA, and anti-CD30 CAR-T therapies. Chills and hypoxia were adverse events most frequently reported for patients undergoing anti-TAG-72 CAR-T treatment, while anti-Mesothelin and anti-CLL-1 CAR-T therapies were the types most commonly associated with electrolyte imbalances. Based on these results, on-target toxicity may account for some of the adverse clinical outcomes associated with these treatments. To fully elucidate CAR-T-associated adverse events profiles, it is thus essential that target information be incorporated into safety databases, in addition to being considered in the context of CAR-T therapy selection and associated patient management.</p>
<p id="p0160">Serious and fatal adverse events were also observed among patients included in this meta-analysis, with 48.70% (690/1418) and 3.20% (146/4574) respectively having experienced serious adverse events and treatment-related deaths. Infections were the most commonly reported serious adverse event and factor associated with treatment-related death, while the most commonly reported non-immune-related adverse event in these respective categories was sepsis. It was also found that infection was more likely to occur in hematologic malignancies and CAR-T with 4-1BB co-stimulation. This study also looked at the incidence of secondary primary malignancy, 7.6% (127/1677), of which myelodysplastic syndrome (1.79%)/acute myeloid leukemia (0.72%) and basal cell carcinoma (0.90%) were probably the most common types. Improving the current understanding of CAR-T-related toxicity is vital to guide the formulation of routine screening programs aimed at detecting signs of treatment-related toxicity and recognizing associated symptoms early point among patients undergoing CAR-T treatment.</p>
<p id="p0165">To explore factors that influence CAR-T-related adverse events, subgroup analyses were conducted. The overall mean incidence of all-grade and grade 3 or higher adverse events was differ significantly between hematologic malignancies (98.40% and 84.21%) and solid tumors (94.66% and 68.88%), bulky tumor (98.48% and 81.71%) and non-bulky tumor (96.71% and 80.95%), and prior receiving (94.93% and 80.66%) and prior non-receiving autologous or allogeneic SCT (87.90% and 76.08%). Identifying patient populations that may have a potential impact on the occurrence of adverse events in a specific subgroup analysis may help to better guide the management of CAR-T patients, enabling clinicians to determine who is most likely to benefit from a stable benefit of CAR-T while more conducive to supporting an individualized treatment plan. In addition, the absence of head-to-head comparisons of different CAR-T regimens also underscores the need for indirect comparisons. Here, five approved CAR-T regimens were not associated with better treatment-related adverse events relative to standard chemotherapy, and comparisons of these five drugs were performed. The drugs that generally exhibited more favorable safety profiles included ciltacabtagene autoleucel (all-grade) and tisagenlecleucel (grade 3 or higher). Anti-CD19 CAR-T treatment and CAR-T cells with a 4-1BB co-stimulatory domain also tended to be safer in these analyses. As this study included published trials with large sample sizes when performing this network meta-analysis, the results offer value as a key reference for personalized treatment planning in clinical settings, while also better equipping clinicians to choose appropriate and safe drugs for cohorts of patients with the same form of cancer.</p>
<p id="p0170">There are multiple limitations to this study. For one, the inclusion of studies with large sample sizes in the pooled analyses performed herein may have contributed to smaller effect sizes and wider CIs. Secondly, this study failed to incorporate risk or proportionality using an inverse probability weighting method based on population weights, which may affect the accuracy of the results, especially when there is selection bias between studies (such as English language limitations and potential confounders in clinical trials). However, we try to adjust for factors that may affect the incidence of adverse events (subgroup analysis). Third, the reliance of this study on the published literature inevitably means that these results will reflect any biases or errors attributable to the included studies, and the results of these pooled analyses will only apply to those patients who would be eligible for the included trials. Fourth, there remains a need to explore the potential effects of other variables on CAR-T-related adverse events, including patient age, manufacturing processes, and region, highlighting an avenue for further study. Sixth, the indirect comparisons herein were based on RCTs with the assumption that the included patients in these trials had comparable characteristics. Caution is thus warranted when interpreting these indirect comparisons, underscoring the need for validation through head-to-head studies in the future. Seventh, in the context of safety data meta-analysis, if some studies incompletely report AE results, the full-case analysis may lead to result bias. We use the Bayesian MAGEC model and consider the left-censored threshold to further reduce the bias. Lastly, the adverse events profiles for different cancer patients undergoing CAR-T therapies have not been characterized in detail, highlighting the importance of large-scale real-world trials addressing this issue.</p>
<p id="p0175">In conclusion, to support the widespread uptake of innovative treatment strategies, data pertaining to both their safety and their efficacy are necessary. Given the limited safety data available for CAR-T regimens, in this study, the incidence of all common treatment-related adverse events, induced secondary primary malignancy types, and causes of death were summarized and characterized in detail. The key findings of these pooled analyses were that CRS and hematologic toxicities are commonly associated with CAR-T therapy. In subgroup analyses, differences in adverse events were noted among antigen targets, cancer types, tumor bulk, number of prior treatment lines, and previously treated with autologous or allogeneic SCT. In summary, large-scale global meta-analyses remain vital as a means of obtaining a clear overview of CAR-T toxicity profiles. The results from this study have the potential to offer a reference for the process of patient selection, guiding clinicians as they seek to design personalized treatment plans and supplement the current limitations in terms of the guidelines available for post-CAR-T treatment care.</p></section><section id="sec5"><h2 class="pmc_sec_title">Contributors</h2>
<p id="p0180"><strong>Hong Zhu:</strong> Conceptualization, Methodology, Software, Resources, Data Curation, Writing-Original Draft, Writing-Review &amp; Editing, Supervision, Project administration, Funding acquisition. <strong>Steven T Rosen and Wei Liu:</strong> Conceptualization, Methodology, Data Curation, Writing-Original Draft, and Writing-Review &amp; Editing. <strong>Youwen Zhu:</strong> Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing-Original Draft, Writing-Review &amp; Editing, Visualization. <strong>Kun Liu:</strong> Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing-Original Draft, Writing-Review &amp; Editing. All authors had full access to the data in the paper and verified the underlying data.</p></section><section id="sec6"><h2 class="pmc_sec_title">Data sharing statement</h2>
<p id="p0185">All authors had full access to all of the data in this study and took complete responsibility for the integrity of the data and the accuracy of the data analysis. The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></section><section id="coi0010"><h2 class="pmc_sec_title">Declaration of interests</h2>
<p id="p0190">All of the authors have indicated that they have no competing interests in the content of the article. This manuscript is original and has not been previously published, nor has it been simultaneously submitted to any other journal.</p></section><section id="ack0010" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p id="p0195">No individual other than the co-authors listed contributed to this publication.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="appsec2">
<sup>Appendix A</sup><p class="display-inline" id="p0205">Supplementary data related to this article can be found at <a href="https://doi.org/10.1016/j.eclinm.2025.103267" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.eclinm.2025.103267</a>.</p>
</div></div></section><section id="appsec1"><h2 class="pmc_sec_title">Appendix A. Supplementary data</h2>
<section class="sm xbox font-sm" id="mmc1"><div class="caption p"><span>Supplementary Figures and Tables</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12273842/bin/mmc1.pdf" data-ga-action="click_feat_suppl" class="usa-link">mmc1.pdf</a><sup> (11.9MB, pdf) </sup>
</div></div></section></section><section id="cebib0010" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="cebib0010_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="bib1">
<span class="label">1.</span><cite>Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733. doi: 10.1056/NEJMoa1103849.</cite> [<a href="https://doi.org/10.1056/NEJMoa1103849" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3387277/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21830940/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Chimeric%20antigen%20receptor-modified%20T%20cells%20in%20chronic%20lymphoid%20leukemia&amp;author=D.L.%20Porter&amp;author=B.L.%20Levine&amp;author=M.%20Kalos&amp;author=A.%20Bagg&amp;author=C.H.%20June&amp;volume=365&amp;issue=8&amp;publication_year=2011&amp;pages=725-733&amp;pmid=21830940&amp;doi=10.1056/NEJMoa1103849&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib2">
<span class="label">2.</span><cite>June C.H., O'Connor R.S., Kawalekar O.U., Ghassemi S., Milone M.C. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365. doi: 10.1126/science.aar6711.</cite> [<a href="https://doi.org/10.1126/science.aar6711" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29567707/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=CAR%20T%20cell%20immunotherapy%20for%20human%20cancer&amp;author=C.H.%20June&amp;author=R.S.%20O'Connor&amp;author=O.U.%20Kawalekar&amp;author=S.%20Ghassemi&amp;author=M.C.%20Milone&amp;volume=359&amp;issue=6382&amp;publication_year=2018&amp;pages=1361-1365&amp;pmid=29567707&amp;doi=10.1126/science.aar6711&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib3">
<span class="label">3.</span><cite>Boyiadzis M.M., Dhodapkar M.V., Brentjens R.J., et al.  Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6(1):137. doi: 10.1186/s40425-018-0460-5.</cite> [<a href="https://doi.org/10.1186/s40425-018-0460-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6278156/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30514386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Chimeric%20antigen%20receptor%20(CAR)%20T%20therapies%20for%20the%20treatment%20of%20hematologic%20malignancies:%20clinical%20perspective%20and%20significance&amp;author=M.M.%20Boyiadzis&amp;author=M.V.%20Dhodapkar&amp;author=R.J.%20Brentjens&amp;volume=6&amp;issue=1&amp;publication_year=2018&amp;pages=137&amp;pmid=30514386&amp;doi=10.1186/s40425-018-0460-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib4">
<span class="label">4.</span><cite>Wang D., Wang J., Hu G., et al.  A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 2021;137(21):2890–2901. doi: 10.1182/blood.2020008936.</cite> [<a href="https://doi.org/10.1182/blood.2020008936" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33512480/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=A%20phase%201%20study%20of%20a%20novel%20fully%20human%20BCMA-targeting%20CAR%20(CT103A)%20in%20patients%20with%20relapsed/refractory%20multiple%20myeloma&amp;author=D.%20Wang&amp;author=J.%20Wang&amp;author=G.%20Hu&amp;volume=137&amp;issue=21&amp;publication_year=2021&amp;pages=2890-2901&amp;pmid=33512480&amp;doi=10.1182/blood.2020008936&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib5">
<span class="label">5.</span><cite>Del Bufalo F., De Angelis B., Caruana I., et al.  GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284–1295. doi: 10.1056/NEJMoa2210859.</cite> [<a href="https://doi.org/10.1056/NEJMoa2210859" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37018492/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=GD2-CART01%20for%20relapsed%20or%20refractory%20high-risk%20neuroblastoma&amp;author=F.%20Del%20Bufalo&amp;author=B.%20De%20Angelis&amp;author=I.%20Caruana&amp;volume=388&amp;issue=14&amp;publication_year=2023&amp;pages=1284-1295&amp;pmid=37018492&amp;doi=10.1056/NEJMoa2210859&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib6">
<span class="label">6.</span><cite>Mackensen A., Haanen J., Koenecke C., et al.  CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844–2853. doi: 10.1038/s41591-023-02612-0.</cite> [<a href="https://doi.org/10.1038/s41591-023-02612-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10667102/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37872225/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=CLDN6-specific%20CAR-T%20cells%20plus%20amplifying%20RNA%20vaccine%20in%20relapsed%20or%20refractory%20solid%20tumors:%20the%20phase%201%20BNT211-01%20trial&amp;author=A.%20Mackensen&amp;author=J.%20Haanen&amp;author=C.%20Koenecke&amp;volume=29&amp;issue=11&amp;publication_year=2023&amp;pages=2844-2853&amp;pmid=37872225&amp;doi=10.1038/s41591-023-02612-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib7">
<span class="label">7.</span><cite>Qi C., Liu C., Gong J., et al.  Claudin 18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30(8):2224–2234. doi: 10.1038/s41591-024-03037-z.</cite> [<a href="https://doi.org/10.1038/s41591-024-03037-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38830992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Claudin%2018.2-specific%20CAR%20T%20cells%20in%20gastrointestinal%20cancers:%20phase%201%20trial%20final%20results&amp;author=C.%20Qi&amp;author=C.%20Liu&amp;author=J.%20Gong&amp;volume=30&amp;issue=8&amp;publication_year=2024&amp;pages=2224-2234&amp;pmid=38830992&amp;doi=10.1038/s41591-024-03037-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib8">
<span class="label">8.</span><cite>Schett G., Müller F., Taubmann J., et al.  Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024;20(9):531–544. doi: 10.1038/s41584-024-01139-z.</cite> [<a href="https://doi.org/10.1038/s41584-024-01139-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39107407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Rheumatol&amp;title=Advancements%20and%20challenges%20in%20CAR%20T%20cell%20therapy%20in%20autoimmune%20diseases&amp;author=G.%20Schett&amp;author=F.%20M%C3%BCller&amp;author=J.%20Taubmann&amp;volume=20&amp;issue=9&amp;publication_year=2024&amp;pages=531-544&amp;pmid=39107407&amp;doi=10.1038/s41584-024-01139-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib9">
<span class="label">9.</span><cite>Mao R., Hussein M.S., He Y. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours. Expert Rev Mol Med. 2022;24:e7. doi: 10.1017/erm.2021.32.</cite> [<a href="https://doi.org/10.1017/erm.2021.32" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9617572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35086597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Mol%20Med&amp;title=Chimeric%20antigen%20receptor%20engineered%20T%20cells%20and%20their%20application%20in%20the%20immunotherapy%20of%20solid%20tumours&amp;author=R.%20Mao&amp;author=M.S.%20Hussein&amp;author=Y.%20He&amp;volume=24&amp;publication_year=2022&amp;pages=e7&amp;pmid=35086597&amp;doi=10.1017/erm.2021.32&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib10">
<span class="label">10.</span><cite>Sumransub N., El Jurdi N., Chiraphapphaiboon W., Maakaron J.E. Putting function back in dysfunction: endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies. Blood Rev. 2022;51 doi: 10.1016/j.blre.2021.100883.</cite> [<a href="https://doi.org/10.1016/j.blre.2021.100883" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34429234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Rev&amp;title=Putting%20function%20back%20in%20dysfunction:%20endothelial%20diseases%20and%20current%20therapies%20in%20hematopoietic%20stem%20cell%20transplantation%20and%20cellular%20therapies&amp;author=N.%20Sumransub&amp;author=N.%20El%20Jurdi&amp;author=W.%20Chiraphapphaiboon&amp;author=J.E.%20Maakaron&amp;volume=51&amp;publication_year=2022&amp;pmid=34429234&amp;doi=10.1016/j.blre.2021.100883&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib11">
<span class="label">11.</span><cite>Flugel C.L., Majzner R.G., Krenciute G., et al.  Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49–62. doi: 10.1038/s41571-022-00704-3.</cite> [<a href="https://doi.org/10.1038/s41571-022-00704-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10278599/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36418477/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=Overcoming%20on-target,%20off-tumour%20toxicity%20of%20CAR%20T%20cell%20therapy%20for%20solid%20tumours&amp;author=C.L.%20Flugel&amp;author=R.G.%20Majzner&amp;author=G.%20Krenciute&amp;volume=20&amp;issue=1&amp;publication_year=2023&amp;pages=49-62&amp;pmid=36418477&amp;doi=10.1038/s41571-022-00704-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib12">
<span class="label">12.</span><cite>Lei W., Xie M., Jiang Q., et al.  Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis. Cancers (Basel) 2021;13(15) doi: 10.3390/cancers13153912.</cite> [<a href="https://doi.org/10.3390/cancers13153912" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8345443/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34359816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Treatment-related%20adverse%20events%20of%20chimeric%20antigen%20receptor%20T-cell%20(CAR%20T)%20in%20clinical%20trials:%20a%20systematic%20review%20and%20meta-analysis&amp;author=W.%20Lei&amp;author=M.%20Xie&amp;author=Q.%20Jiang&amp;volume=13&amp;issue=15&amp;publication_year=2021&amp;pmid=34359816&amp;doi=10.3390/cancers13153912&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib13">
<span class="label">13.</span><cite>Luo W., Li C., Zhang Y., et al.  Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC Cancer. 2022;22(1):98. doi: 10.1186/s12885-021-09102-x.</cite> [<a href="https://doi.org/10.1186/s12885-021-09102-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8785493/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35073859/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Adverse%20effects%20in%20hematologic%20malignancies%20treated%20with%20chimeric%20antigen%20receptor%20(CAR)%20T%20cell%20therapy:%20a%20systematic%20review%20and%20Meta-analysis&amp;author=W.%20Luo&amp;author=C.%20Li&amp;author=Y.%20Zhang&amp;volume=22&amp;issue=1&amp;publication_year=2022&amp;pages=98&amp;pmid=35073859&amp;doi=10.1186/s12885-021-09102-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib14">
<span class="label">14.</span><cite>Cao J.X., Wang H., Gao W.J., You J., Wu L.H., Wang Z.X. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020;22(4):214–226. doi: 10.1016/j.jcyt.2020.01.015.</cite> [<a href="https://doi.org/10.1016/j.jcyt.2020.01.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32305113/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cytotherapy&amp;title=The%20incidence%20of%20cytokine%20release%20syndrome%20and%20neurotoxicity%20of%20CD19%20chimeric%20antigen%20receptor-T%20cell%20therapy%20in%20the%20patient%20with%20acute%20lymphoblastic%20leukemia%20and%20lymphoma&amp;author=J.X.%20Cao&amp;author=H.%20Wang&amp;author=W.J.%20Gao&amp;author=J.%20You&amp;author=L.H.%20Wu&amp;volume=22&amp;issue=4&amp;publication_year=2020&amp;pages=214-226&amp;pmid=32305113&amp;doi=10.1016/j.jcyt.2020.01.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib15">
<span class="label">15.</span><cite>Page M.J., McKenzie J.E., Bossuyt P.M., et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372 doi: 10.1136/bmj.n71.</cite> [<a href="https://doi.org/10.1136/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8005924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33782057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=The%20PRISMA%202020%20statement:%20an%20updated%20guideline%20for%20reporting%20systematic%20reviews&amp;author=M.J.%20Page&amp;author=J.E.%20McKenzie&amp;author=P.M.%20Bossuyt&amp;volume=372&amp;publication_year=2021&amp;pmid=33782057&amp;doi=10.1136/bmj.n71&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib16">
<span class="label">16.</span><cite>Zhou X., Yao Z., Bai H., et al.  Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265–1274. doi: 10.1016/S1470-2045(21)00333-8.</cite> [<a href="https://doi.org/10.1016/S1470-2045(21)00333-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34391508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Treatment-related%20adverse%20events%20of%20PD-1%20and%20PD-L1%20inhibitor-based%20combination%20therapies%20in%20clinical%20trials:%20a%20systematic%20review%20and%20meta-analysis&amp;author=X.%20Zhou&amp;author=Z.%20Yao&amp;author=H.%20Bai&amp;volume=22&amp;issue=9&amp;publication_year=2021&amp;pages=1265-1274&amp;pmid=34391508&amp;doi=10.1016/S1470-2045(21)00333-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib17">
<span class="label">17.</span><cite>Huang H.Y., Andrews E., Jones J., Skovron M.L., Tilson H. Pitfalls in meta-analyses on adverse events reported from clinical trials. Pharmacoepidemiol Drug Saf. 2011;20(10):1014–1020. doi: 10.1002/pds.2208.</cite> [<a href="https://doi.org/10.1002/pds.2208" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21858897/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacoepidemiol%20Drug%20Saf&amp;title=Pitfalls%20in%20meta-analyses%20on%20adverse%20events%20reported%20from%20clinical%20trials&amp;author=H.Y.%20Huang&amp;author=E.%20Andrews&amp;author=J.%20Jones&amp;author=M.L.%20Skovron&amp;author=H.%20Tilson&amp;volume=20&amp;issue=10&amp;publication_year=2011&amp;pages=1014-1020&amp;pmid=21858897&amp;doi=10.1002/pds.2208&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib18">
<span class="label">18.</span><cite>Wang Y., Zhou S., Yang F., et al.  Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi: 10.1001/jamaoncol.2019.0393.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2019.0393" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6487913/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31021376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Treatment-related%20adverse%20events%20of%20PD-1%20and%20PD-L1%20inhibitors%20in%20clinical%20trials:%20a%20systematic%20review%20and%20meta-analysis&amp;author=Y.%20Wang&amp;author=S.%20Zhou&amp;author=F.%20Yang&amp;volume=5&amp;issue=7&amp;publication_year=2019&amp;pages=1008-1019&amp;pmid=31021376&amp;doi=10.1001/jamaoncol.2019.0393&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib19">
<span class="label">19.</span><cite>Qi X., Zhou S., Peterson C.B., et al.  Meta-analysis of censored adverse events. N Engl J Stat Data Sci. 2024;2(3):380–392. doi: 10.51387/24-nejsds62.</cite> [<a href="https://doi.org/10.51387/24-nejsds62" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11845246/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39991459/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Stat%20Data%20Sci&amp;title=Meta-analysis%20of%20censored%20adverse%20events&amp;author=X.%20Qi&amp;author=S.%20Zhou&amp;author=C.B.%20Peterson&amp;volume=2&amp;issue=3&amp;publication_year=2024&amp;pages=380-392&amp;pmid=39991459&amp;doi=10.51387/24-nejsds62&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib20">
<span class="label">20.</span><cite>Zhu Y., Liu K., Zhu H. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis. Int J Gynecol Cancer. 2024;34(10):1570–1579. doi: 10.1136/ijgc-2024-005296.</cite> [<a href="https://doi.org/10.1136/ijgc-2024-005296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38901970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Gynecol%20Cancer&amp;title=Immune%20checkpoint%20inhibitor%20combinations%20for%20patients%20with%20advanced%20endometrial%20cancer:%20a%20network%20meta-analysis%20and%20cost-utility%20analysis&amp;author=Y.%20Zhu&amp;author=K.%20Liu&amp;author=H.%20Zhu&amp;volume=34&amp;issue=10&amp;publication_year=2024&amp;pages=1570-1579&amp;pmid=38901970&amp;doi=10.1136/ijgc-2024-005296&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib21">
<span class="label">21.</span><cite>Stang A., Poole C., Kuss O. The ongoing tyranny of statistical significance testing in biomedical research. Eur J Epidemiol. 2010;25(4):225–230. doi: 10.1007/s10654-010-9440-x.</cite> [<a href="https://doi.org/10.1007/s10654-010-9440-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20339903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Epidemiol&amp;title=The%20ongoing%20tyranny%20of%20statistical%20significance%20testing%20in%20biomedical%20research&amp;author=A.%20Stang&amp;author=C.%20Poole&amp;author=O.%20Kuss&amp;volume=25&amp;issue=4&amp;publication_year=2010&amp;pages=225-230&amp;pmid=20339903&amp;doi=10.1007/s10654-010-9440-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib22">
<span class="label">22.</span><cite>Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557.</cite> [<a href="https://doi.org/10.1136/bmj.327.7414.557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC192859/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12958120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Measuring%20inconsistency%20in%20meta-analyses&amp;author=J.P.%20Higgins&amp;author=S.G.%20Thompson&amp;author=J.J.%20Deeks&amp;author=D.G.%20Altman&amp;volume=327&amp;issue=7414&amp;publication_year=2003&amp;pages=557-560&amp;pmid=12958120&amp;doi=10.1136/bmj.327.7414.557&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib23">
<span class="label">23.</span><cite>Cumpston M., Li T., Page M.J., et al.  Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142. doi: 10.1002/14651858.ED000142.</cite> [<a href="https://doi.org/10.1002/14651858.ED000142" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10284251/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31643080/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cochrane%20Database%20Syst%20Rev&amp;title=Updated%20guidance%20for%20trusted%20systematic%20reviews:%20a%20new%20edition%20of%20the%20Cochrane%20Handbook%20for%20Systematic%20Reviews%20of%20Interventions&amp;author=M.%20Cumpston&amp;author=T.%20Li&amp;author=M.J.%20Page&amp;volume=10&amp;issue=10&amp;publication_year=2019&amp;pages=Ed000142&amp;pmid=31643080&amp;doi=10.1002/14651858.ED000142&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib24">
<span class="label">24.</span><cite>Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.</cite> [<a href="https://doi.org/10.1136/bmj.315.7109.629" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2127453/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9310563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Bias%20in%20meta-analysis%20detected%20by%20a%20simple,%20graphical%20test&amp;author=M.%20Egger&amp;author=G.%20Davey%20Smith&amp;author=M.%20Schneider&amp;author=C.%20Minder&amp;volume=315&amp;issue=7109&amp;publication_year=1997&amp;pages=629-634&amp;pmid=9310563&amp;doi=10.1136/bmj.315.7109.629&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib25">
<span class="label">25.</span><cite>Hunter J.P., Saratzis A., Sutton A.J., Boucher R.H., Sayers R.D., Bown M.J. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol. 2014;67(8):897–903. doi: 10.1016/j.jclinepi.2014.03.003.</cite> [<a href="https://doi.org/10.1016/j.jclinepi.2014.03.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24794697/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Epidemiol&amp;title=In%20meta-analyses%20of%20proportion%20studies,%20funnel%20plots%20were%20found%20to%20be%20an%20inaccurate%20method%20of%20assessing%20publication%20bias&amp;author=J.P.%20Hunter&amp;author=A.%20Saratzis&amp;author=A.J.%20Sutton&amp;author=R.H.%20Boucher&amp;author=R.D.%20Sayers&amp;volume=67&amp;issue=8&amp;publication_year=2014&amp;pages=897-903&amp;pmid=24794697&amp;doi=10.1016/j.jclinepi.2014.03.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib26">
<span class="label">26.</span><cite>Zhou Z., Tian Z., Peterson C.B., Bao L., Zhou S. Shiny-MAGEC: a Bayesian R Shiny application for meta-analysis of censored adverse events 2025 March 01. arXiv. 2025 <a href="https://ui.adsabs.harvard.edu/abs/2025arXiv250305982Z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ui.adsabs.harvard.edu/abs/2025arXiv250305982Z</a> Available from:</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=arXiv&amp;title=Shiny-MAGEC:%20a%20Bayesian%20R%20Shiny%20application%20for%20meta-analysis%20of%20censored%20adverse%20events%202025%20March%2001&amp;author=Z.%20Zhou&amp;author=Z.%20Tian&amp;author=C.B.%20Peterson&amp;author=L.%20Bao&amp;author=S.%20Zhou&amp;publication_year=2025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bib27">
<span class="label">27.</span><cite>Chen L.R., Li Y.J., Zhang Z., et al.  Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: a meta-analysis. Front Oncol. 2022;12 doi: 10.3389/fonc.2022.924208.</cite> [<a href="https://doi.org/10.3389/fonc.2022.924208" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9682079/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36439485/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Cardiovascular%20effects%20associated%20with%20chimeric%20antigen%20receptor%20T%20cell%20therapy%20in%20cancer%20patients:%20a%20meta-analysis&amp;author=L.R.%20Chen&amp;author=Y.J.%20Li&amp;author=Z.%20Zhang&amp;volume=12&amp;publication_year=2022&amp;pmid=36439485&amp;doi=10.3389/fonc.2022.924208&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Supplementary Figures and Tables</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12273842/bin/mmc1.pdf" data-ga-action="click_feat_suppl" class="usa-link">mmc1.pdf</a><sup> (11.9MB, pdf) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from eClinicalMedicine are provided here courtesy of <strong>Elsevier</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1016/j.eclinm.2025.103267"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/main.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (792.9 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12273842/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12273842/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12273842%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12273842/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12273842/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12273842/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40687742/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12273842/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40687742/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12273842/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12273842/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="x7ZCth1Faje3BA2enAXuE62jfnGIT517HHoNk1aMUHMioJpHo6CA1THzjAPrWIP9">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-B7-tgZZA.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-BLbQGH8u.js"></script>
    
    

    </body>
</html>
